Newly diagnosed pediatric AML trial with extra treatment options
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies different treatment plans for children and teens newly diagnosed with AML (a type of blood cancer). Depending on the child's tumor markers and risk group, they may be offered an extra drug (quizartinib) or a targeted antibody (Mylotarg) to see if it improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with AML that started on its own (not caused by another cancer treatment or bone marrow problem).
- You must be between 1 day and 18 years old at diagnosis.
- You and your family must agree to the study plan and follow-up visits.
- You cannot have had chemotherapy or radiation before for any reason.
- You cannot have certain other conditions like Down syndrome leukemia, APL, MDS, or JMML.
- You must have normal heart function and be willing to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study adds a targeted drug called quizartinib to standard chemotherapy for children with a certain type of acute myeloid leukemia (AML) that has a FLT3-ITD gene change. The goal is to see if this combination is safe and effective for treating newly diagnosed patients.
This trial compares standard chemotherapy with newer drug combinations (CPX-351 and gilteritinib) for children and young adults with acute myeloid leukemia (AML), a type of blood cancer. It aims to find which treatment works better and who might benefit from targeted therapy based on specific genetic changes (FLT3 mutations).
This study tests a new way to monitor and treat AML in children and young adults after their first chemotherapy. It aims to improve outcomes by closely tracking the disease and adjusting treatment as needed.
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Hear when a new Acute Myeloid Leukemia in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.